Get the Stockscreener App
15.65
9.29%
1.33
After Hours:
15.34
-0.31
-1.98%
Mesoblast Ltd Adr stock is traded at $15.65, with a volume of 317.48K.
It is up +9.29% in the last 24 hours and down -7.45% over the past month.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
See More
Previous Close:
$14.32
Open:
$15.06
24h Volume:
317.48K
Relative Volume:
1.29
Market Cap:
$2.02B
Revenue:
$65.48M
Net Income/Loss:
$-94.46M
P/E Ratio:
-21.22
EPS:
-0.7375
Net Cash Flow:
$-71.18M
1W Performance:
+6.97%
1M Performance:
-7.45%
6M Performance:
-4.05%
1Y Performance:
+10.91%
1-Day Range:
$15.06
$15.89
1-Week Range:
$14.02
$15.89
52-Week Range:
$9.61
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
15.65 | 1.85B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
MESO Ignites 10% Surge: A Biotech Spark Ignited Without a Visible Fuse - Bitget
Philip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
Mesoblast issues 5 million unquoted warrants as fee for US$50 million convertible note facility - MSN
Mesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
MEOBF SEC FilingsMesoblast 10-K, 10-Q, 8-K Forms - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Sahm
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
FARM 51 GROUP S.A.ZY -,1.XFRA: MWBMUHANDELSUNTERBRECHUNGTEIL 5 - aktiencheck.de
Mesoblast stock reaches 52-week high at 21.05 USD - Investing.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com India
Mesoblast announces board leadership changes as company evolves - Investing.com South Africa
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - inkl
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Secures Up To US$50 Mln In Convertible Note Agreements With Key Investors - Nasdaq
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall (NASDAQ:MESO) - Seeking Alpha
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
MESOMesoblast Ltd ADR Short Interest - Finviz
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd Share Price ADR Each Representing 10 Ord Shares SPON - Hargreaves Lansdown
MESO Financial Statements & ChartsMesoblast LtdAdr MacroTrends - CMLviz
MESO Pivot Points, Technical Analysis and Moving AveragesMesoblast LtdAdr Technicals - CMLviz
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod - Yahoo Finance
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Novartis
How many stocks fighting COVID-19 have maintained their momentum? - Stockhead
Mesoblast Stock Soars on Promise of Cellular Medicine - Nanalyze
MESO Stock Price and Chart — NASDAQ:MESO - TradingView
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):